MEDTIDE(03880)

30.260+0.0000.00%

Market data delayed 15 minutes

    • 小富即安
      ·
      08-22
      Comment
      Report
      koolgal
      ·
      08-22
      🌟🌟🌟In the first half of 2025, $HKEX(00388)$ posted its best ever revenue - HKD 141.1 billion, up 33% year on year.  Profits surged 39%.  Daily turnover? HKD 222.8 billion, up 122%.  These are not just numbers.  It shows that Hong Kong stock market is buzzing again.  It is a story of resilience and grit.  With new reforms such as paperless listing, smart IPO pricing, lower trading thresholds -  these are great moves that will power $HKEX(00388)$ to new record highs in the future.  I am super excited at these new developments. It is time for $HKEX(00388)$ to shine.🚀🚀🚀🌛🌛🌛💰💰💰

      【🎁港財報季暴漲靚股】港交所公佈創紀錄盈利,收入和溢利創新高!你點看?

      @財報話你知
      小虎們,隨着恆生指數重返25000點,港股IPO熱潮持續,港交所2025年中期業績出爐,利潤和收入再創歷史新高,一起來看看吧~~~[Sly]上半年收入創歷史新高!8月20日,香港交易及結算所有限公司發佈2025年中期業績,財報虎只能說依舊讓人驚喜不斷:收入及其他收益同比增長33%至140.76億港元,股東應佔溢利為85.19億港元,同比增長39%,兩者均創歷史新高![Miser]其中2025年Q2淨利潤同比增長41%至44.42億港元,港交所表示主要是因為港股現貨市場的成交量增長所帶動的交易及結算費用的增加。[Cool]圖源:港交所我們來看看具體項目:證券市場上半年平均每日成交額為2402億元,同比增長118%;期貨及期權產品平均每日成交合約張數超過170萬張,同比增長11%;香港ETF市場增長更加亮眼,平均每日成交金額達338億元,同比增加184%;交易費及交易系統使用費同比增長49%至49億港元;結算及交收費同比增長48.5%至31.55億港元;滬深港通收入及其他收益創歷年半年度新高,達18.13億港元,其中將近80%來自交易及結算收費;南向港股通日均成交額高達1110億港元,是2024年同期三倍。不僅如此,港交所依舊慷慨派息,宣佈中期派息為每股6港元,同比增長38%,以現金派付。今年以來,恆生指數累計升幅超25%,國企指數與恆生科技指數均累計升幅超23%,港交所股價升超50%,上個月底,港交所股價創下年內新高的452港元。[Grin]圖源:港交所財報香港重奪全球最大IPO桂冠!IPO這一方面財報虎需要給大家重點聊一聊,這也是港交所的焦點所在:2025年上半年,香港市場迎來44家公司,募資金額超過1000億港元,同比增長716%,創下港交所自2021年以來的最佳半年度表現,重奪全球最大IPO桂冠![Miser]最大規模的還是「寧王」寧德時代,募資410億港元,成為202
      【🎁港財報季暴漲靚股】港交所公佈創紀錄盈利,收入和溢利創新高!你點看?
      🌟🌟🌟In the first half of 2025, $HKEX(00388)$ posted its best ever revenue - HKD 141.1 billion, up 33% year on year. Profits surged 39%. Daily turnov...
      TOPJamesWalton: Incredible numbers! So exciting! 🚀💰
      7
      Report
      财神小宝贝
      ·
      07-01
      Comment
      Report
      Bk125
      ·
      06-30
      $MEDTIDE(03880)$ Stop loss 29.95
      03880
      06-30 09:52
      HKMEDTIDE
      SidePrice | FilledRealized P&L
      Buy
      Open
      31.15
      200
      --
      Closed
      MEDTIDE
      $MEDTIDE(03880)$ Stop loss 29.95
      2
      Report
    • Company Profile

      Company Name
      MEDTIDE
      Market
      SEHK
      Establishment Date
      - -
      Employees
      - -
      Office Location
      - -
      Zip Code
      - -
      Phone
      - -
      Fax
      - -
      Introduction
      Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.
      • 1D
      • 5D
      • Day
      • Week
      • Month

      Loading ...

      High
      30.360
      Open
      30.160
      Volume%
      1.09
      Low
      30.020
      Close
      30.260
      T/O Rate
      0.10%
       
       
       
       

      Most Discussed